Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied
These results confirmed the efficacy and safety of CagriSema in the more metabolically complex population of patients with both obesity and type 2 diabetes
When used with insulin or sulfonylureas, GLP-1 RAs may increase hypoglycaemia risk, requiring dose adjustments of these medications
Benefits: pectins are soluble fibers that slow digestion and promote the release of satiety hormones like GLP-1 and PYY
Pharmaceutics 14 (9), 1890
Increased energy expenditure must complement reduced food intake in order to maintain weight loss since physiological compensatory adaptations protect against major weight decrement: decreased caloric intake leads to increased hunger, lower sensitivity to satiety factors, and a reduced metabolic rate [83, 84]
